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Abstract
Cyclic nucleotide phosphodiesterase 3A (PDE3A) hydrolyzes cAMP to AMP, but is competitively inhibited
by cGMP due to a low kcat despite a tight Km. Cyclic AMP elevation is known to inhibit all pathways of
platelet activation, and thus regulation of PDE3 activity is significant. Although cGMP elevation will inhibit
platelet function, the major action of cGMP in platelets is to elevate cAMP by inhibiting PDE3A. To
investigate the molecular details of how cGMP, a similar but not identical molecule to cAMP, behaves as
an inhibitor of PDE3A, we constructed a molecular model of the catalytic domain of PDE3A based on
homology to the recently determined X-ray crystal structure of PDE4B. Based on the excellent fit of this
model structure, we mutated nine amino acids in the putative catalytic cleft of PDE3A to alanine using
site-directed mutagenesis. Six of the nine mutants (Y751A, H840A, D950A, F972A, Q975A, and F1004A)
significantly decreased catalytic efficiency, and had kcat/Km less than 10% of the wild-type PDE3A using
cAMP as substrate. Mutants N845A, F972A, and F1004A showed a 3- to 12-fold increase of Km for cAMP.
Four mutants (Y751A, H840A, D950A, and F1004A) had a 9- to 200-fold increase of Ki for cGMP in
comparison to the wild-type PDE3A. Studies of these mutants and our previous study identified two groups
of amino acids: E866 and F1004 contribute commonly to both cAMP and cGMP interactions while N845,
E971, and F972 residues are unique for cAMP and the residues Y751, H836, H840, and D950 interact with
cGMP. Therefore, our results provide biochemical evidence that cGMP interacts with the active site residues
differently from cAMP.
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Unlike most tissues, but similar to other blood cells, an
increased intracellular level of cAMP is associated with the
inhibition of all platelet responses to agonists including such
responses as shape change, aggregation, adhesion, and gran-
ule release (Salzman and Weisenberger 1972). Cyclic AMP
is synthesized by adenylate cyclase under control of PGI2
and PGE1, PGD2 and adenosine acting on separate recep-
tors coupled to Gs protein. cAMP acting through protein
kinase A inhibits agonist binding and phosphoinositide hy-
drolysis to diacetyl glycerol and IP3. cAMP phosphodies-
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terases catalyze the degradation of cAMP. In contrast, ago-
nists such as thrombin, ADP, and epinephrine antagonize
the stimulation of adenylate cyclase by acting on Gi.
The catalytic regions of the 11 known families of cyclic
nucleotide phosphodiesterases are well conserved (Soder-
ling and Beavo 2000). In contrast, the regulatory regions
comprising sites for phosphorylation, cGMP binding, and
membrane insertion vary widely. Metallohydrolases, espe-
cially those binding catalytic zinc, require three ligands di-
rectly coordinating the metal ion as well as a fourth ligand,
usually H2O. The amino acid residues commonly found to
act as zinc ligands are histidine and glutamate, and, more
rarely, aspartate or cysteine. The three-ligand arrangement
on a polypeptide chain also shows a highly predictable pat-
tern. In all 11 families of cyclic nucleotide phosphodiester-
ases (Soderling and Beavo 2000), there is absolute conser-
vation of two motifs, HNXXH(X)24–26E and HDXXH(X)24–26E.
In the case of PDE3, a unique 44 amino acid insert lies
between the second histidine and the glutamate of the first
motif (Meacci et al. 1992).
Platelets contain two cAMP phosphodiesterases: the high
Km cyclic GMP-stimulated PDE2A and the low Km cGMP-
inhibited PDE3A (Hidaka and Asano 1976). Platelets also
contain the specific cGMP phosphodiesterase, PDE5A. We
have focused on the major cAMP phosphodiesterase in
platelets, PDE3A, which we purified to homogeneity (Grant
and Colman 1984). We cloned the enzyme from HEL cells,
which are known to express megakaryocyte/platelet pro-
teins, since mRNA levels are very low in platelets and li-
braries are hard to construct (Cheung et. al. 1996). The
resulting cDNA sequence was identical to a cloned enzyme
from human myocardium (Meacci et al. 1992). To begin to
define the region of the active site, we made four deletion
mutants of HEL cell PDE3A. Two had full activity, but the
two smaller ones did not, indicating that the active site lay
between amino acids 679 and 1141 (Cheung et al. 1996).
As a first step to elucidate the catalytic mechanism of
PDE3A, we performed and previously published chemical
modification studies on the histidines present in the catalytic
domain of the enzyme, isolated from human platelets with
diethyl pyrocarbonate (DEP) (Ghazaleh et al. 1996). This
reaction resulted in a time- and concentration-dependent
inactivation and hydroxylamine promptly reactivated
PDE3A consistent with modification of histidines. The in-
activation was accompanied by an increase in a difference
spectrum at 240 nm consistent with N-carbethoxylation of
histidine residues. The extrapolated value for complete in-
activation shows that 2.0 mols of histidine per mol of the
enzyme are responsible for most of the loss in PDE3A ac-
tivity. AMP protects two histidine groups against 14C-DEP
incorporation, and cGMP also protects two histidine groups.
However, when both nucleotides are included, four groups
are protected, indicating that cAMP and cGMP each pro-
tects two different groups. These results suggest but do not
prove that there are different cAMP and cGMP sites. How-
ever, the fact that cGMP is a competitive inhibitor led to the
hypothesis that the sites may overlap.
In a second study, we therefore produced six-point mu-
tations of conserved histidines and glutamic acid residues in
the catalytic domain of PDE3A (Fig. 1) (Zhang and Colman
2000). Despite adequate expression, H752 and H756 had
activities of less than 0.1% of the wild type due to effects on
catalysis and/or metal binding. Two of the mutants showed
significantly different Km for cAMP. E866A exhibited a
10-fold increase and E971A a 5-fold increase. Thus, these
two amino acids lie in the cAMP binding site. When cGMP
was tested as an inhibitor, the Ki for the first histidine of the
second motif, H836A, showed a 178-fold increase in Ki and
the related glutamate residue, E866A, showed a 27-fold
increase in the Ki of cGMP. The data indicates that these
two amino acids display defective interactions with cGMP.
Thus, E866 lies in both the cGMP and cAMP sites, H836
only in the cGMP site, and E971 in the cAMP site. These
observations confirmed our hypothesis that the sites overlap
and account for the behavior of cGMP as a competitive
inhibitor.
To better interpret these results and to rationally design
new mutants, we have now created a molecular homology
model of PDE3A based on the three-dimensional structure
of the catalytic region (residues 152–528) of PDE4B2B (Xu
et al. 2000), the only three-dimensional structure of PDE
currently determined. In addition, the sequence homology
of the catalytic region of PDE4B2B is over 50%. We chose
five nonconserved residues which constituted the putative
boundaries of a deep pocket thought to be the catalytic cleft
in the molecule. We also examined four additional con-
served residues which lay close to identified residues in the
cAMP and/or cGMP binding sites previously described
(Zhang and Colman 2000). The description of the molecular
model and the characterization of these amino acids by site-
directed mutagenesis to alanine form the basis of this report.
Results
Modeling of cAMP/cGMP binding
The binding of cAMP to PDE4B active site was built on the
basis of the electron density for the structure of PDE4B (Xu
et al. 2000) and the structure of PDE4B complexed to
cAMP (Ke et al., unpubl.). The model of cAMP binding to
PDE3A was generated from the superposition between
PDE3A and PDE4B (Fig. 2). In this model, the phosphate
portion of cAMP is located next to Zn and forms hydrogen
bonds with His752 as well as the Zn binding residues of
Asp837 and Asp950 (Fig. 3). The sugar group of cAMP
forms van der Waals interactions with Tyr751, Leu910, and
Ile968 while the adenine ring of cAMP interacts with hy-
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drophobic residues of Phe972, Phe989, and Phe1004. This
binding geometry is consistent with the prediction reported
earlier (Xu et al. 2000).
Based on the model of cAMP, the binding of cGMP was
manually built into the active site of PDE3A (Fig. 4). Since
the difference between cAMP and cGMP occurs on the base
rings of the nucleotides, we feel that cGMP and cAMP must
have similar molecular conformation and the phosphate por-
tion of cGMP and cAMP must have similar binding. How-
ever, the orientation of the guanine ring is uncertain because
the volume of the active site (440 Å3) (Xu et al. 2000) is
significantly larger than that of cGMP (estimated 250 Å3).
In addition, unlike PDE3A, PDE4B does not bind cGMP in
its active site and thus no structure with cGMP is available.
There are two ways that cGMP can be modeled. The first
model is that the guanine of cGMP occupies the similar
location as the adenine of cAMP. In this model, the residues
interacting with cGMP will be essentially identical to
cAMP. However, the extra atom N2 of guanine might form
a hydrogen bond with a backbone oxygen of the Phe989
loop. The results suggest that cGMP or its hydrolysis prod-
uct GMP will be sequestered in the active site to inhibit the
PDE3A activity. However, the hydrolysis of cGMP pro-
ceeds at only one-tenth the rate of cAMP and cGMP is an
inhibitor with a Ki  200 nM, so that effectively cGMP
acts as an inhibitor. A sequence comparison showed that the
loop Ser987–Pro988–Phe989–Met990 in PDE3A is highly
variable. Thus, the different amino acid components in this
loop might contribute to the differentiation of cGMP from
cAMP by PDE3A and might also play a critical role in the
substrate specificity of different PDE families.
In the second model which is preferred and displayed
(Fig. 4), we have placed the phosphate portion of cGMP
into a similar position to that of cAMP while the guanine
ring orients to a different hydrophobic pocket that is com-
prised of His913, Phe914, Phe1004, and Ile1008. In this
model, the phosphate group of cGMP contacts His752
and Asp950 in a similar way as cAMP, and the sugar group
of cGMP remains to interact with Tyr751 and Leu910
but no longer with Ile968. The dramatic change is that
the guanine of cGMP is located in a different hydropho-
bic pocket and forms van der Waals interactions with
Phe1004 and Phe1008 and a hydrogen bond with His913.
The presence of the hydrogen bond between His913 and the
guanine ring will lock cGMP at the active site to inhibit
PDE3A.
Fig. 1. Alignment of the catalytic domain PDE3A with PDE4B. Positions where sequences of all 11mammalian family members are
identical are noted with asterisks. Locations of mutants generated in this study are indicated in black boxes. The mutants made in the
previous experiments (Zhang and Colman 2000) are displayed in gray boxes.
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Mutagenesis
Eight new mutants were made and one, H840, previously
made in yeast (Cheung et al. 1996) was reconstructed in SF9
insect cells for more careful analysis. In each case, the cho-
sen amino acid was mutated to alanine. Five mutants (T844,
N845, L910, F972, and Q975) were chosen by reference to
the homology model to represent the boundaries of the pu-
tative substrate binding site. Three (Y751, D950, and
F1004) were highly conserved (Fig. 1) and found to lie in
the putative active site (Fig. 3). The mutants were analyzed
by SDS electrophoreses and each was a single band of 60
kD (Fig. 5). Similarly, on a Western blot, a single band was
detected with anti-PDE3A antibody for each mutation
(Fig. 6).
Table 1 presents the kinetic data. The kcat of the mutants
ranged from 0.35% to 77% of recombinant PDE3A, and a
similar range was noted for the catalytic efficiency kcat/Km.
We defined a third amino acid which lies in the cAMP site
with a Km elevated 13-fold (F1004); a fourth amino acid,
N845, with a Km elevated 4-fold; and a fifth, F972, with a
Km elevated 3-fold. We also have located four additional
amino acids in the cGMP site that markedly increased the
Ki: Y751A, 8.8-fold increase; D950A, 53-fold increase;
H840A, 69-fold increase; and F1004A, over 130-fold. Fig.
7A illustrates representative determinations of the Km for
cAMP for the mutants N845A and F1004A. Figure 7B
presents a sample determination of the Ki for cGMP for the
mutant Y751A. The value is nine times the Ki for recom-
binant PDE3A.
Correlations of mutagenesis results with the model
The Ki values for the mutants proposed to alter cGMP in-
teractions are 10- to over 100-fold elevated compared to the
recombinant PDE3A consistent with the hypothesis that H-
bonds are involved. Although the cGMP binding model
needs to be confirmed by crystal structures, our site-directed
mutagenesis supports the model of different binding of
cGMP from cAMP and agrees with the previous differential
protection of the nucleotides against histidine modification
(Ghazaleh et al. 1996). Among the nine amino acids that
have been mutated to alanine, Thr844, Asn845, and Gln975
have no interactions with the current models of cAMP and
cGMP, consistent with the mutagenesis that the mutants
showed no substantial impact on the catalytic activity and
binding affinity of the nucleotides. Phe1004 interacts with
both bases of cAMP and cGMP and its mutation to alanine
resulted in about 300-fold decrease of kcat/Km of cAMP and
over 100-fold increase of Ki of cGMP (Table 1), indicating
the critical role of Phe1004 for cGMP binding and catalytic
activity. An interesting residue is Asp950 that interacts with
zinc and also forms hydrogen bond with phosphate group of
cAMP/cGMP (Figs. 3 and 4). Mutation of Asp950 to ala-
nine resulted in a net loss of 100-fold in catalytic activity
and 50-fold in cGMP binding. Mutation of the residues
Tyr751, Leu910, and Phe972 that interact with either cAMP
or cGMP showed significant impact on the catalytic activity
and nucleotide binding.
Discussion
Two previous studies from our laboratory employing site-
directed mutagenesism (Cheung et al. 1998; Zhang and Col-
man 2000) have focused on the 26 perfectly conserved
amino acids in PDE2, PDE3A, PDE4B, and PDE5A (Turko
et al. 1998). A total of 12 conserved amino acids were
mutated in the two studies with particular emphasis on the
two canonical metal binding motifs, HNXXH and HDXXH,
with the associated “downstream” acidic residue in this case
glutamate. Although preliminary conclusions about some of
the amino acids involved in catalysis and cAMP and cGMP
interaction sites were suggested, without a molecular model
the spatial proximity of these residues could not be visual-
ized.
The three-dimensional atomic structure of the catalytic
domain of PDE4B2B (Xu et al. 2000) provided consider-
able insight into the mechanism of catalysis and specificity
of PDE4. Ultimate understanding of the catalytic properties
and the binding of metals, substrates, and inhibitors of
Fig. 2. Homology model of PDE3A. Superposition of C atoms of PDE4B
catalytic domain (yellow) over a PDE3A model (green). The zinc position
is marked with a ball, while the red stick represents a model of PDE3A
inhibitor clostamide.
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PDE3A will await the crystallization of the enzyme. In the
interim, we prepared a molecular model of PDE3A which
could be used to select new amino acids for mutation and to
integrate previous observations. We also have used the in-
formation about the metal binding residues and cAMP bind-
ing residues of PDE4B to help interpret our data. The un-
altered immunoreactivity of the mutations and their muta-
tion to alanine minimizes but does not rule out
conformational changes due to different patterns of folding.
The structure of the catalytic domain residues 152–528 of
PDE4B2B is made up of 17 alpha helixes which fold into
three subdomains. At the junction of these domains is a deep
pocket which accommodates the substrate cAMP and two
metal ions. Twenty-one conserved amino acids lie within or
near this pocket (Xu et al. 2000) and both metal ions are
located near the bottom. One of the metals, Zn++, is bound
with high affinity and assumed to be structural, and its role
in catalysis is uncertain. Previously, the mutations H752A
and H756A exhibited less than one-thousandth the catalytic
efficiency of the truncated wild-type enzyme without ap-
preciable change in the Km for cAMP or the Ki of cGMP.
We assumed that Zn++ at the bottom of the active site in
PDE3A is in the homologous position to that in PDE4 crys-
tal and interacts with H756 of PDE3A. Both amino acid
residues H752 and H756 are probably involved in the ca-
talysis or Zn++ binding (Xu et al. 2000). It is possible that
these two histidines are the ones protected by cAMP against
the inactivation by DEP (Ghazaleh et al. 1996). H752 in
PDE3A are fully prepared to protonate the O3 linkage and
is stabilized by hydrophobic ring stacking including Y751
and H840.
The results of this study were combined with our previ-
ous investigation (Zhang and Colman 2000). Taken to-
gether, we identified five amino acids (N845, E866, E971,
F972, and F1004) which showed an increase of the Km for
cAMP ranging from 3- to 13-fold when they are mutated to
alanine. The model for cAMP has a high probability of
being accurate since the position of cAMP is very similar to
that of cAMP in the structure of the crystal of PDE4B. To
decide whether there is significant interaction between the
amino acid residues and the nucleotides, we have taken 3.5
to 4Å representing the hydrophobic interactions. The best
examples of this are F972, F989, and F1004 (Fig. 3), which
form the boundaries of the deep concave hydrophobic
pocket for accommodation of adenine moiety of cAMP, and
correspond to hydrophobic pocket residues F414, M431,
and F446 in PDE4B (Xu et al. 2000). The residues N845
and E866, while not close enough to cAMP to be considered
in the binding site, are gatekeepers which guard the opening
to the active site cleft and thus prevent cAMP from entering
the pocket. The final amino acid we have identified as in-
teracting with cAMP, E971, corresponds to E413 in PDE4B
Fig. 3. Model of cAMP binding site. The nine residues mutated in this study and the two residues, E866 and E971, previously
identified as involved in cAMP binding (Zhang and Colman 2000) are shown as is the position of the Zn++ atom against the alpha
carbon backbone ribbon of the PDE3A homology model. The positioning of cAMP is described in Materials and Methods.
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which stabilizes H234 (H752 in PDE3A), a known partici-
pant in catalysis probably through the second metal required
for enzymatic activity. The binding of this residue to a metal
may cause a conformational change bringing it closer to
cAMP which is not represented by the model. The model
supports the lack of interaction of T844, L910, and Q975
mutations, which does not affect the kinetic behavior of the
enzyme with cAMP or cGMP while F1004 is involved in
both cGMP and cAMP binding.
We have also identified six amino acids that increase the
Ki for cGMP from 9- to 200-fold (Fig. 4). Two, F1004 and
E866, are common to both cyclic nucleotides and have been
Fig. 4. Model of cGMP binding site. The nine residues mutated in this study and the two residues, E866 and H836, previously
identified as involved in cGMP binding (Zhang and Colman 2000) are shown in a similar way as in Figure 3.
Fig. 5. Analysis of purified proteins of PDE3A by SDS-PAGE gel. Re-
combinant PDE3A and mutant proteins were separated in 12% SDS-PAGE
gel and proteins were detected by Coomassie blue stain.
Fig. 6. Analysis of the purified mutant proteins using Western blotting.
Recombinant PDE3A and mutant proteins were resolved using 10% SDS-
PAGE gel and transferred to nitrocellulose membranes. The membrane was
probed with anti-platelet PDE3A antibody.
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discussed above. D950 is predicted to form at least one
hydrogen bond with cGMP and thus helps to fix its position
in the molecule. Y751 is close enough to participate in van
der Waals-type interactions. The corresponding amino acid
in PDE5A, Y603, is considered one of the main contributors
to the binding of cGMP, the substrate of PDE5A (Turko et
al. 1998). Although H836 and H840 are not within 4Å of
cGMP in its current orientation, a previous study identified
two histidines protected by cGMP against interaction by
DEP (Ghazaleh et al. 1996). By analogy to PDE4B, H836 is
a ligand for Zn++ and thus may in PDE3A be closer to
cGMP than currently predicted by this model. H840 is per-
fectly conserved in the 11 PDE families and may be in-
volved in binding of the additional metal ion such as Mn++
necessary for catalysis but whose exact location is still un-
clear. It should be noted that these two histidines are among
the most quantitatively perturbed by mutation as judged by
the 176-fold and 69-fold increase in Ki for cGMP.
All of these assignments in PDE3A structure are based on
the kinetic properties of the mutants, but the spatial prop-
erties are based on the molecular model. Because PDE4B
does not bind cGMP in its active site, the exact position of
this nucleotide is less certain than cAMP. The hypotheses
regarding the interactions of cGMP particularly remain to
be confirmed or denied when a three-dimensional structure
is available for the PDE3A catalytic domain.
Materials and methods
Materials
3[H]-cAMP was purchased from Amersham Pharmacia Biotech .
Oligonucleotides were synthesized by Life Technologies, Inc.
cAMP, cGMP, and other reagents used in this study were pur-
chased from Sigma unless stated otherwise.
Expression of PDE3A mutants
Expression of PDE3A mutants in a baculovirus system and prepa-
ration of Sf9 lysates were as described (Zhang and Colman 2000).
Briefly, the vector pBS3031 was digested by XhoI and SacI. The
DNA fragment coding for PDE3A was subcloned into baculovirus
vector pBlueBacHis2B (Invitrogen) which has a hexahistidine-tag
to generate pBBH3031. Sf9 cells were cotransfected with
pBBH3031 and linearized AcMNPV DNA (Invitrogen) to produce
recombinant viruses using lipofection as previously described
(Zhang and Colman 2000). After 96 h infection by the recombinant
virus, the cells were collected and sonicated in a lysis buffer (50
mmole/L Tris-HCl, pH 7.8, 10 mmole/L MgCl2 with 0.5 g/mL
pepstatin, 0.5 g/mL leupeptin, 2 mole/L benzamidine, 10 g/
mL soybean trypsin inhibitor and 50 mole/L tosyl phenylalanyl
chloromethylketone). Cell debris was removed by centrifugation at
15,000g for 30 min at 4°C. The supernatant was either stored at
–80°C or further purified.











PDE3A 0.21 ± 0.023 189.0 ± 23.6 8.58 0.76 ± 0.11
Y751A 0.53 ± 0.03 10.6 ± 1.56 0.20 6.71 ± 0.60
H840A 0.46 ± 0.03 0.68 ± 0.03 0.015 52.2 ± 8.6
T844A 0.35 ± 0.02 45.20 ± 1.58 1.29 0.46 ± 0.10
N845A 0.92 ± 0.26 146.0 ± 24.19 1.58 0.88 ± 0.062
L910A 0.50 ± 0.07 29.6 ± 2.65 0.593 1.72 ± 0.15
D950A 0.23 ± 0.01 1.81 ± 0.10 0.076 40.1 ± 2.26
F972A 0.65 ± 0.10 36.5 ± 3.15 0.562 1.67 ± 0.07
Q975A 0.24 ± 0.05 21.1 ± 2.20 0.878 0.24 ± 0.02
F1004A 272 ± 0.61 8.68 ± 4.26 0.031 >100
All determinations represent the mean ± SD of at least three separate
experiments. The bold values of Km and Ki are at least 3-fold elevated
compared to recombinant PDE3A and the differences are statistically sig-
nificant (P < 0.001) using Student’s t-test.
Fig. 7. Kinetic analysis of PDE3A and mutants. Double-reciprocal Lin-
eweaver-Burk plots derived from kinetic curves are shown. The assays
were performed as described under “Experimental Procedures”. A plot of
a typical measurement out of three determinations is depicted for each of
three mutants. Panel A shows the Km values of recombinant PDE3A,
N845A, and F1004A were determined with Lineweaver-Burk plots. Panel
B shows the Ki of cGMP for mutant Y751A was calculated in presence of
various concentrations of cGMP.
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Construction of PD3A mutants
All PDE3A mutants were constructed using a QuikChange Kit
(Stratagene) as described previously (Zhang and Colman 2000).
Pairs of complementary oligonucleotide primers that contain de-




















(9) F1004A, CAGGAATCCGCCATCTCTCACATTG-3 and
5-CAATGTGAGAGATGGCGGATTCCTG-3.
The altered bases are underlined. PBlueBacHis3031 plasmid
DNA was employed as a template of PCR with Pfu DNA poly-
merase. The PCR products were treated with Dpn I in order to
digest the parent double strand DNA chains. The top 10 E. coli
competent cells were used for all transformations. Plasmid DNA
was purified using a QIAGEN Inc. Plasmid Miniprep kit according
to the manufacturer’s protocol (QIAGEN). The sequences of mu-
tants were confirmed by automated DNA sequencing.
Purification of PDE3A mutants and Western
blot analysis
The histidine-tagged PDE3A proteins were purified on a Ni++-
NTA column as previously described (Zhang and Colman 2000).
Proteins in Sf9 cells lystes were separated by SDS-PAGE gel
electrophoresis in 10% gel and transferred to nitrocellulose mem-
brane. The membrane was blocked in TNA buffer containing 5%
nonfat dry milk and 0.05% Tween 20 for 1.5 h at room tempera-
ture, and then incubated with anti-platelet PDE3A polyclonal an-
tibody (1:1000 dilution) in TNA buffer for another 1 h. After
washing the membrane three times, the immunoreactivity was de-
tected with horseradish-conjugated anti-rabbit IgG. Bands were
visualized with substrate system (Bio-Rad) according to the manu-
facturer’s protocol.
PDE activity assay
Enzymatic activity was measured in a total volume of 0.1 mL
containing 50 mmole/L Tris-HCl pH 7.8, 10 mmole/L MgCl2, and
3H-cAMP (40,000 cpm/assay) at 24°C for 30 min. The reactions
were terminated by addition of 0.2 mL of 0.2 mole/L ZnSO4 and
0.2 mL of 0.2 mole/L Ba(OH)2. The samples were vortexed and
centrifuged at 10,000g for 3 min. The labeled product of the re-
action 3H-5 AMP was precipitated with BaSO4, and the unreacted
3H-cAMP remained in the supernatant. Radioactivity in the super-
natant was determined by liquid scintillation counter. Km and kcat
were calculated by Lineweaver-Burk plot with various concentra-
tions of cAMP by Microsoft Excel Program. The Km, Ki, and kcat
values were expressed as mean ± SD for three independent mea-
surements. It would have been desirable to determine Km for
cGMP hydrolysis. However, cGMP is primarily a competitive in-
hibitor. Since the kcat is more than 10-fold less than cAMP, it is
difficult to accurately measure the Km. Therefore, we used the Ki
as a measure of the affinity of PDE3A for cGMP.
Protein assay
Protein concentrations were measured using bicinchoninic acid
Protein Assay Reagent Kit (Pierce Chemical Company) with bo-
vine serum albumin as a standard.
Molecular modeling
Members of the phosphodiesterase protein families display pri-
mary sequence homology and ternary structure conservation for
their catalytic domains. The crystal structure of the catalytic do-
main of PDE4B (Xu et al. 2000) was used as a template to build
the model of a highly related protein, human platelet cGMP in-
hibited cAMP phosphodiesterase (PDE3A). The model was built
manually by the systematic side chain replacement (Baglia et al.
1991) according to the sequence alignment shown in Fig. 1. The
small (1–5 amino acids) amino acid insertions/deletions between
PDE4B and PDE3A were manually realigned to accommodate the
three-dimensional structure. After loop grafting, explicit hydro-
gens were added and the final structure was subjected to four
cycles of dynamics (200 steps)/minimization (50 steps) followed
by minimization to energy convergence. Minimization was done
by the conjugate gradient method using Kollman All-Atom force
field and Gasteiger-Huckle charges at the dielectric constant 4 and
non-bonded cut-off 12A. The cAMP model was built into the
active site of PDE4 according to the electron density in the com-
plex structure of PDE4-cAMP (Ke et al. unpubl.). Based on the
model of cAMP, the binding of cGMP was manually built into the
active site of PDE3A by using program O (Jones 1982).
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